🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsProgress & Lab Results[PREMIUM] Size 28 to size 8 — clothing transformation photos + measurement log Page 2

[PREMIUM] Size 28 to size 8 — clothing transformation photos + measurement log

JenMemphis Thu, Apr 9, 2026 at 4:41 PM 25 replies 941 viewsPage 2 of 5
KevinCompounds
VIP Member
5,432
18,234
Dec 2023
Nevada
Apr 9, 2026 at 7:31 PM#6

Pancreatitis risk from hypertriglyceridemia typically becomes significant above 500 mg/dL, with acute pancreatitis risk really escalating above 1000 mg/dL. At 358 you were in a gray zone. At 152, that specific risk is negligible.

Regarding statins: with an LDL-C of 108 and a prior ApoB of 158, I'd want to see the updated ApoB before making a definitive call. If your ApoB is still above 90-100 mg/dL, adding a moderate-intensity statin would be reasonable. The lipid-lowering effects of GLP-1 agonists and statins work through different mechanisms (statins upregulate LDL receptor expression; GLP-1 agonists reduce hepatic lipid production), so they're complementary rather than redundant.

Your non-HDL-C of 138 is still above the ideal target of <130 for moderate risk. There's room for further optimization.

29 20jennifer_SEA, tyler_CSCS, VanRx_Mike and 26 others
Reply Quote Save Share Report
NicoleRaleigh
Member
356
1,567
Aug 2024
Raleigh, NC
Apr 9, 2026 at 7:48 PM#7

This thread is gold. I'm on semaglutide 1.7mg (not at 2.4 yet) and my TGs went from 220 to 165 in 4 months. Not as dramatic as OP but still meaningful. What I really want to know: does tirzepatide have a lipid advantage over semaglutide because of the GIP component? Or is it just about weight loss magnitude?

Last edited: Apr 9, 2026 at 8:48 PM
26 14MikeFit_NJ, InsuranceTom, WendyG_ATL and 23 others
Reply Quote Save Share Report
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
Apr 9, 2026 at 8:05 PM#8

There's emerging evidence that GIP receptor agonism contributes independently to lipid improvements, particularly for triglycerides. GIP receptors are expressed on adipocytes and play a role in lipid storage and lipoprotein lipase activity.

In the SURPASS-2 trial (tirzepatide vs. semaglutide 1 mg head-to-head), tirzepatide showed greater triglyceride reductions even after adjusting for the difference in weight loss. This suggests a pharmacological advantage beyond just more weight loss.

That said, your 25% TG reduction on semaglutide 1.7 mg is solid. The incremental benefit of switching to tirzepatide for lipids alone probably wouldn't justify it unless there are other reasons (greater weight loss, better glucose control, etc.).

3 7LibrarianMeg, bri_stats, pete_manc_UK
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Apr 9, 2026 at 8:22 PM#9

Great clinical discussion. Just a reminder for readers: lipid panels should be drawn fasting (at least 9-12 hours) for accurate triglyceride measurement. If you're seeing dramatically different results, confirm the fasting status was consistent between draws. Non-fasting TGs can be 20-30% higher and lead to misleading comparisons.

Last edited: Apr 9, 2026 at 10:22 PM
23 12SleepFixSam, PurityPaulOR, MaxMetOK and 20 others
Reply Quote Save Share Report

Similar Threads

100 lbs lost in 14 months — comprehensive DEXA and lab data16 replies
12-month metabolic panel comparison — before and after GLP-122 replies
A1C from 9.2 to 5.4 in 8 months — my diabetes reversal journey16 replies
6-month body recomposition — DEXA, labs, progress photos22 replies
1-year semaglutide anniversary — honest review with all data16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register